Outcomes at one year demonstrated that high-degree mismatching did not adversely affect patient survival when PTCy was ...

Critically, metastatic recurrence has significant prognostic implications. In this cohort, patients who experienced ...

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and ...

Lisocabtagene maraleucel is the first CAR T-cell therapy approved for relapsed or refractory MZL, expanding treatment options ...

Initial data from a phase 2 (NCT05256290) clinical trial show that silevertinib yields robust antitumor activity and ...

Oncology and primary care often operate in silos, leading to communication gaps and unclear roles in patient care management.

Despite significant advancements in medical technology and procedural safety, the speaker emphasizes that relapse remains the ...

Sabari, MD, assistant professor at NYU Grossman School of Medicine in New York, discussed the phase 3 IMforte trial ...

With the 2025 American Society of Hematology (ASH) Meeting & Exposition kicking off on Saturday, December 6, in Orlando, Florida, Targeted Oncology is bringing you background on the most exciting ...

QBS72S, a LAT1-targeted agent, shows potential in treating leptomeningeal disease, improving survival rates in metastatic ...

A recent study highlights the critical impact of comorbidities on survival rates in melanoma patients, emphasizing the need ...

LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative ...